-
Je něco špatně v tomto záznamu ?
Role of membrane cholesterol in differential sensitivity of muscarinic receptor subtypes to persistently bound xanomeline
A. Randáková, E. Dolejší, V. Rudajev, P. Zimčík, V. Doležal, EE. El-Fakahany, J. Jakubík,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- agonisté muskarinových receptorů farmakokinetika MeSH
- buněčná membrána účinky léků metabolismus MeSH
- CHO buňky cytologie MeSH
- cholesterol metabolismus MeSH
- Cricetulus MeSH
- inositolfosfáty metabolismus MeSH
- magnetická rezonanční spektroskopie MeSH
- molekulární modely MeSH
- průtoková cytometrie MeSH
- pyridiny farmakokinetika MeSH
- radioligandová zkouška MeSH
- receptory muskarinové genetika metabolismus MeSH
- simulace molekulového dockingu MeSH
- thiadiazoly farmakokinetika MeSH
- tritium farmakokinetika MeSH
- vápník metabolismus MeSH
- zvířata MeSH
- Check Tag
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Xanomeline (3-(Hexyloxy)-4-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-thiadiazole) is a muscarinic agonist that is considered to be functionally selective for the M1/M4 receptor subtypes. Part of xanomeline binding is resistant to washing. Wash-resistant xanomeline activates muscarinic receptors persistently, except for the M5 subtype. Mutation of leucine 6.46 to isoleucine at M1 or M4 receptors abolished persistent activation by wash-resistant xanomeline. Reciprocal mutation of isoleucine 6.46 to leucine at the M5 receptor made it sensitive to activation by wash-resistant xanomeline. Lowering of membrane cholesterol made M1 and M4 mutants and M5 wild type receptors sensitive to activation by wash-resistant xanomeline. Molecular docking revealed a cholesterol binding site in the groove between transmembrane helices 6 and 7. Molecular dynamics showed that interaction of cholesterol with this binding site attenuates receptor activation. We hypothesize that differences in cholesterol binding to this site between muscarinic receptor subtypes may constitute the basis for xanomeline apparent functional selectivity and may have notable therapeutic implications. Differences in receptor-membrane interactions, rather than in agonist-receptor interactions, represent a novel possibility to achieve pharmacological selectivity. Our findings may be applicable to other G protein coupled receptors.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19000935
- 003
- CZ-PrNML
- 005
- 20220406090133.0
- 007
- ta
- 008
- 190107s2018 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.neuropharm.2018.01.027 $2 doi
- 035 __
- $a (PubMed)29407765
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Randáková, Alena $u Institute of Physiology Czech Academy of Sciences, 142 20 Prague, Czech Republic.
- 245 10
- $a Role of membrane cholesterol in differential sensitivity of muscarinic receptor subtypes to persistently bound xanomeline / $c A. Randáková, E. Dolejší, V. Rudajev, P. Zimčík, V. Doležal, EE. El-Fakahany, J. Jakubík,
- 520 9_
- $a Xanomeline (3-(Hexyloxy)-4-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-thiadiazole) is a muscarinic agonist that is considered to be functionally selective for the M1/M4 receptor subtypes. Part of xanomeline binding is resistant to washing. Wash-resistant xanomeline activates muscarinic receptors persistently, except for the M5 subtype. Mutation of leucine 6.46 to isoleucine at M1 or M4 receptors abolished persistent activation by wash-resistant xanomeline. Reciprocal mutation of isoleucine 6.46 to leucine at the M5 receptor made it sensitive to activation by wash-resistant xanomeline. Lowering of membrane cholesterol made M1 and M4 mutants and M5 wild type receptors sensitive to activation by wash-resistant xanomeline. Molecular docking revealed a cholesterol binding site in the groove between transmembrane helices 6 and 7. Molecular dynamics showed that interaction of cholesterol with this binding site attenuates receptor activation. We hypothesize that differences in cholesterol binding to this site between muscarinic receptor subtypes may constitute the basis for xanomeline apparent functional selectivity and may have notable therapeutic implications. Differences in receptor-membrane interactions, rather than in agonist-receptor interactions, represent a novel possibility to achieve pharmacological selectivity. Our findings may be applicable to other G protein coupled receptors.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a CHO buňky $x cytologie $7 D016466
- 650 _2
- $a vápník $x metabolismus $7 D002118
- 650 _2
- $a buněčná membrána $x účinky léků $x metabolismus $7 D002462
- 650 _2
- $a cholesterol $x metabolismus $7 D002784
- 650 _2
- $a Cricetulus $7 D003412
- 650 _2
- $a průtoková cytometrie $7 D005434
- 650 _2
- $a inositolfosfáty $x metabolismus $7 D007295
- 650 _2
- $a magnetická rezonanční spektroskopie $7 D009682
- 650 _2
- $a molekulární modely $7 D008958
- 650 _2
- $a simulace molekulového dockingu $7 D062105
- 650 _2
- $a agonisté muskarinových receptorů $x farmakokinetika $7 D018721
- 650 _2
- $a pyridiny $x farmakokinetika $7 D011725
- 650 _2
- $a radioligandová zkouška $7 D011869
- 650 _2
- $a receptory muskarinové $x genetika $x metabolismus $7 D011976
- 650 _2
- $a thiadiazoly $x farmakokinetika $7 D013830
- 650 _2
- $a tritium $x farmakokinetika $7 D014316
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Dolejší, Eva $u Institute of Physiology Czech Academy of Sciences, 142 20 Prague, Czech Republic.
- 700 1_
- $a Rudajev, Vladimír, $u Institute of Physiology Czech Academy of Sciences, 142 20 Prague, Czech Republic. $d 1977- $7 jo20211124170
- 700 1_
- $a Zimčík, Pavel $u Institute of Physiology Czech Academy of Sciences, 142 20 Prague, Czech Republic.
- 700 1_
- $a Doležal, Vladimír $u Institute of Physiology Czech Academy of Sciences, 142 20 Prague, Czech Republic.
- 700 1_
- $a El-Fakahany, Esam E $u Department of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis, MN 55455, USA.
- 700 1_
- $a Jakubík, Jan $u Institute of Physiology Czech Academy of Sciences, 142 20 Prague, Czech Republic. Electronic address: jakubik@biomed.cas.cz.
- 773 0_
- $w MED00003497 $t Neuropharmacology $x 1873-7064 $g Roč. 133, č. - (2018), s. 129-144
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29407765 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190107 $b ABA008
- 991 __
- $a 20220406090128 $b ABA008
- 999 __
- $a ok $b bmc $g 1364904 $s 1039058
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 133 $c - $d 129-144 $i 1873-7064 $m Neuropharmacology $n Neuropharmacology $x MED00003497
- LZP __
- $a Pubmed-20190107